Caught in a Covid-19 mael­strom, Eli Lil­ly locks down clin­i­cal tri­als as multi­bil­lion-dol­lar R&D ops de­rail

The Covid-19 pan­dem­ic has de­railed Eli Lil­ly’s $6 bil­lion R&D op­er­a­tions.

The phar­ma gi­ant re­port­ed Mon­day morn­ing that it has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.